The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review explores in detail the aspects of HCV innate and treatment-induced resistance to new interferon-free DAA regimens.

Ceccherini-Silberstein, F., Cento, V., Di Maio, V.C., Perno, C.F., & Craxì, A. (2018). Viral resistance in HCV infection. CURRENT OPINION IN VIROLOGY, 32, 115-127 [10.1016/j.coviro.2018.10.005].

Viral resistance in HCV infection

Ceccherini-Silberstein, Francesca;Di Maio, Velia Chiara;Perno, Carlo Federico;
2018

Abstract

The introduction of new multi-genotypic direct acting antivirals (DAA) in clinical practice has revolutionized HCV treatment, permitting the achievement of >95% rates of sustained virological response in many patients. However, virological failures can occur particularly if the treatments are sub optimal and/or with too short duration. Failure is often associated with development of resistance. The wide genetic variability in terms of different genotypes and subtypes, together with the natural presence and/or easy development of resistance during treatment, are intrinsic characteristics of HCV that may affect the treatment outcome and the chances of achieving a virological cure. This review explores in detail the aspects of HCV innate and treatment-induced resistance to new interferon-free DAA regimens.
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/07 - Microbiologia e Microbiologia Clinica
eng
Antiviral Agents; Drug Therapy, Combination; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Ribavirin; Treatment Failure; Drug Resistance, Multiple, Viral
Ceccherini-Silberstein, F., Cento, V., Di Maio, V.C., Perno, C.F., & Craxì, A. (2018). Viral resistance in HCV infection. CURRENT OPINION IN VIROLOGY, 32, 115-127 [10.1016/j.coviro.2018.10.005].
Ceccherini-Silberstein, F; Cento, V; Di Maio, Vc; Perno, Cf; Craxì, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
CoviroHCVresistenzaFCS2019.pdf

non disponibili

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 373.87 kB
Formato Adobe PDF
373.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2108/219571
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 7
  • ???jsp.display-item.citation.isi??? 8
social impact